| Literature DB >> 27284400 |
Fay Karpouzis1, Rod Bonello2, Mario Pribicevic3, Allan Kalamir3, Benjamin T Brown3.
Abstract
BACKGROUND: Reviews indicate that the quality of reporting of randomised controlled trials (RCTs) in the medical literature is less than optimal, poor to moderate, and require improving. However, the reporting quality of chiropractic RCTs is unknown. As a result, the aim of this study was to assess the reporting quality of chiropractic RCTs and identify factors associated with better reporting quality. We hypothesized that quality of reporting of RCTs was influenced by industry funding, positive findings, larger sample sizes, latter year of publication and publication in non-chiropractic journals.Entities:
Keywords: Chiropractic manipulation; Manipulation; Musculoskeletal; Quality of reporting; Randomised controlled trials; Spinal manipulative therapy; Spine; The CONSORT statement
Year: 2016 PMID: 27284400 PMCID: PMC4899907 DOI: 10.1186/s12998-016-0099-6
Source DB: PubMed Journal: Chiropr Man Therap ISSN: 2045-709X
Fig. 1Flow diagram of RCT selection (N = 35)
Inclusion and exclusion criteria
| Inclusion Criteria |
| RCTs with parallel or cross-over study design |
| Adult study populations with musculoskeletal and non-musculoskeletal with conditions or no condition |
| Chiropractic high-velocity, low-amplitude (HVLA), musculoskeletal manipulation |
| Treatment must include chiropractic manipulation, either spinal or peripheral (or both) with/without adjunctive therapy (mobilization, soft tissue therapy, massage, traction, electro-therapies, ultrasound, exercise advice, ergonomic advice, hot/cold therapy, back education) |
| Comparators: HVLA, placebo, sham treatment or conventional/standard/usual care treatment, or no treatment |
| Exclusion Criteria |
| Reviews, systematic reviews and meta-analyses |
| Non-randomised trial designs (quasi-experimental, observational studies) |
| Pilot or feasibility studies |
| Studies with n-of-1 |
| Studies evaluating diagnostic tests, prevention, prognosis, cost-effectiveness, pathophysiological or mechanophysiological mechanisms, validation of questionnaires |
| Trials not reported as full papers (abstracts), editorials, commentaries, letters, case reports or series, audits, guidelines, historical articles |
| Methodological/Protocol, epidemiological and qualitative studies |
| Studies reporting updates of previously published RCTs |
Frequencies of CONSORT 2010 items from customized overall quality of reporting checklist (N = 35)
| Item | Criterion | CONSORT Description | Total | % |
|---|---|---|---|---|
| 1a | Title | Identification as a randomised trial in the title | 26 | 74 |
| 1b | Abstract | Structured summary of trial design, methods, results, and conclusions | 35 | 100 |
| 2a | Background | Scientific background and explanation of rationale | 35 | 100 |
| 2b | Specific objectives or hypotheses | 34 | 97 | |
| 3a | Trial Design | Description of trial design (such as parallel, factorial) | 18 | 51 |
| 4a | Participants | Eligibility criteria for participants | 34 | 97 |
| 4b | settings and locations where the data were collected | 17 | 49 | |
| 5 | Interventions | The interventions for each group with sufficient details to allow replication, including how they were administered | 32 | 91 |
| 6a | Outcomes | Completely defined pre-specified primary and secondary outcome measures | 32 | 91 |
| 7a | Sample size | How sample size was determined | 25 | 71 |
| 8a | Sequence generation | Method used to generate the random allocation sequence | 29 | 83 |
| 9 | Allocation concealment | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 31 | 87 |
| 10 | Implementation | Was implementation discussed. Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 26 | 74 |
| 11ai | Blinding | Whether or not participants, were blinded to group assignment | 16 | 46 |
| 11aii | Whether those assessing the outcomes were blinded to group assignment | 25 | 71 | |
| 12a | Statistical methods | Statistical methods used to compare groups for outcome(s) | 35 | 100 |
| 13a | Participant flow | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome | 29 | 83 |
| 13b | For each group, losses and exclusions after randomization, together with reasons | 20 | 57 | |
| 14a | Recruitment | Dates defining the periods of recruitment and follow-up | 23 | 66 |
| 15 | Baseline data | A table showing baseline demographic | 32 | 91 |
| 16i | Numbers Analysed | Number of participants (denominator) in each group included in each analysis; state the results in absolute numbers when feasible (e.g., 10/20, not 50 %) | 16 | 46 |
| 16ii | “Intention-to-treat” analysis | 21 | 60 | |
| 17ai | Outcomes and estimation | Primary outcome: a summary of results for each group and the estimated effect size and its precision (e.g., 95 % confidence interval) | 26 | 74 |
| 17aii | Secondary outcome: a summary of results for each group and the estimated effect size and its precision (e.g., 95 % confidence interval) | 25 | 71 | |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | 4 | 11 | |
| 18 | Ancillary Analyses | Results of other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified | 7 | 20 |
| 19 | Adverse events | All adverse events or side effects in each intervention group | 22 | 63 |
| 20 | Limitations | Trial limitations | 31 | 89 |
| 23 | Registration | Registration number | 19 | 54 |
| 25 | Funding | Sources of funding and other support | 32 | 91 |
Legend: Total: Total number of trials reporting item; %: Percentage of trials reporting item
Frequencies of CONSORT for Non-Pharmacological Treatment statement items from customised overall quality of reporting checklist (N = 35)
| Item | Criterion | CONSORT Description | Total | % |
|---|---|---|---|---|
| 1ext | Abstract | Does abstract include-description of the experimental treatment, comparator, care providers, centers, and blinding status | 11 | 31 |
| 3ext | Methods | When applicable, eligibility criteria for centers and those performing the interventions (at least one) | 13 | 37 |
| 4aext | Interventions | Description of the different components of the interventions and, when applicable, descriptions of the procedure for tailoring the interventions to individual participants | 29 | 83 |
| 4bext | Details of how the interventions were standardised (if training was administered) | 11 | 31 | |
| 4cext | Details of how adherence of care providers with the protocol was assessed or enhanced | 1 | 3 | |
| 8ext | Randomization | When applicable, how care providers were allocated to each trial group | 11 | 31 |
| 13ext | Flow Diagram | The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center | 3 | 9 |
| New Item | Details of the experimental treatment and comparator as they were implemented | 8 | 23 | |
| 15ext | Baseline data | Description of care providers (case volume, qualification, expertise, etc.) and centers | 8 | 23 |
Legend: Total: Total number of trials reporting item; %: Percentage of trials reporting item; ext: extension criteria from CONSORT for Non-Pharmacological Treatments
Frequencies of key methodological items from the customised CONSORT checklist (N = 35)
| Item No. | Criterion | CONSORT Description | Total | % |
|---|---|---|---|---|
| 9 | Allocation concealment | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 31 | 87 |
| 11ai | Blinding | Whether or not participants, were blinded to group assignment | 16 | 46 |
| 11aii | Blinding | Whether those assessing the outcomes were blinded to group assignment | 25 | 71 |
| 16ii | Numbers Analysed | “Intention-to-treat” analysis | 21 | 60 |
Legend: Total: the total number of RCTs that reported this item; %: Percentage of trials reporting item
Univariate and multivariate regression analysis for overall quality of reporting score vs exploratory variables (N = 35)
| Univariate Regression Analysis | |||||
| Exploratory Variables | Mean Difference | SE | t |
| 95 % CI |
| Year of Publication | 1.35 | 0.27 | 4.99 | 0.000 a | 0.80, 1.90 |
| Journal Type | 5.81 | 1.77 | 3.28 | 0.002 a | 2.21, 9.42 |
| Sample Size Group | 5.05 | 1.84 | 2.75 | 0.010 a | 1.31, 8.80 |
| Industry Funding | 2.35 | 2.02 | 1.16 | 0.253 | −1.76, 6.46 |
| Positive Finding | 3.30 | 2.18 | 1.51 | 0.140 | −1.14, 7.74 |
| Multivariate Regression Analysis | |||||
| Year of Publication (1) | 1.26 | 0.24 | 5.17 | 0.000 a | 0.76, 1.76 |
| Sample Size Group (1) | 4.19 | 1.39 | 3.01 | 0.005 a | 1.36, 7.02 |
| Year of Publication Grp (2) | 8.16 | 1.73 | 4.73 | 0.000 a | 4.64, 11.67 |
| Sample Size Group (2) | 4.56 | 1.45 | 3.15 | 0.004 a | 1.61, 7.51 |
Legend: a statistically significant result; SE Standard Error; t t-test statistic; CI Confidence Interval; Grp Group; (1) Multivariate Analysis; (2) Additional analysis
Fig. 2Scatterplot of the correlation between the Overall Quality of Reporting Score and Year of Publication(N = 35)
Fig. 3Boxplot of the distribution of Overall Quality of Reporting Scores for Chiropractic vs Non-Chiropractic Journals (N = 35)
Fig. 4Boxplot of the distribution of Overall Quality of Reporting Scores for Sample Size 1–100 vs >100 (N = 35)
Fig. 5Boxplot of the distribution of Overall Quality of Reporting Scores for Year of Publication by group, 2005–2007 vs 2008–2014 (N = 35)